Tag: Coronavirus

1. A cross-sectional sample of residents from Wuhan, China showed low overall seroprevalence (6.92%) of anti-SARS-CoV-2 antibodies in April 2020. 2. Adjusted seroprevalence was lower amongst self-reported asymptomatic individuals than those with symptoms. Evidence Rating Level: 2 (Good) Study Rundown: Over a year after the novel coronavirus SARS-CoV-2 (COVID-19) was characterized as...
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, there were no hospital admissions for COVID-19 in the ChAdOx1-nCoV-19 group.  Evidence Rating Level: 1 (Excellent) Study Rundown: At the time of this publication, the COVID-19 pandemic continues to burden healthcare systems...
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2. Treatment with tocilizumab did not improve survival among patients. Evidence Rating Level: 1 (Excellent) Study Rundown: Cases pertaining to the coronavirus disease 2019 (Covid-19) have led to severe clinical manifestations...
1. Patients hospitalized with COVID-19 and treated with dexamethasone showed an overall decrease in 28-day mortality compared to those treated with usual care. 2. Dexamethasone treatment had a shorter duration in hospital stay compared to the usual care group. Evidence Rating Level: 1 (Excellent) Study Rundown: Although the majority of coronavirus disease 2019 (COVID-19)...
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2. Treatment with tocilizumab did not improve survival among patients. Evidence Rating Level: 1 (Excellent) Study Rundown: Cases pertaining to the coronavirus disease 2019 (Covid-19) have led to severe...
1. In Washington State, pregnant patients were found to be at a higher risk of SARS-CoV-2 infection. 2. Results were more pronounced if patients belonged to a non-white racial or ethnic group or received their care in a language other than English. Evidence Level Rating: 2 (Good) As the COVID-19 pandemic continues to...
1. Efficacy of the Gam-COVID-Vac (Sputnik V) vaccine against COVID-19 was 91.6%. 2. In the vaccine group, there were no confirmed cases of moderate or severe COVID-19 21 days after the first dose. Evidence Rating Level: 1 (Excellent) Study Rundown: Global efforts to develop safe and effective vaccines for COVID-19 prevention are...
1. Novel SARS-CoV-2 vaccine SCB-2019 was well-tolerated amongst both younger and older adults. 2. SCB-2019 adjuvanted with AS03 or CpG/Alum elicited strong humoral and cellular responses.  Evidence Rating Level: 1 (Excellent) Study Rundown: As the global pandemic of SARS-CoV-2 (COVID-19) continues to ravage healthcare systems around the world, the effort to produce...
1. Patients hospitalized with COVID-19 and treated with dexamethasone showed an overall decrease in 28-day mortality compared to those treated with usual care. 2. Dexamethasone treatment had a shorter duration in hospital stay compared to the usual care group. Evidence Rating Level: 1 (Excellent) Study Rundown: Although the majority of coronavirus disease...
1. Majority of the patients that received high-titer convalescent plasma within 72 hours of mild symptom onset were shown to reduce the coronavirus disease 2019 (COVID-19) severe illness progression. 2. The IgG titer distribution between the treatment group and placebo group revealed a significant difference. Evidence Rating Level: 1 (Excellent) Study Rundown: The number...